(RTTNews) – Regeneron Pharmaceuticals Inc. (REGN) and Sanofi announced topline data from a pivotal, single-arm, open-label trial for the PD-1 inhibitor Libtayo in patients with advanced basal cell carcinoma who had progressed on or were intolerant to prior hedgehog pathway inhibitor therapy.
Libtayo demonstrated clinically meaningful and durable responses in Second-line Advanced Basal Cell Carcinoma. Regeneron and Sanofi plan regulatory submissions in 2020.
Basal Cell Carcinoma is a skin cancer and is the most common cancer worldwide, with approximately two million new cases diagnosed every year in the U.S. alone.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.